<DOC>
	<DOCNO>NCT01846832</DOCNO>
	<brief_summary>The purpose study evaluate efficacy , tolerability , safety 12-weeks treatment TMC435 plus pegylated interferon alfa-2a ( PegIFNα-2a ) ribavirin ( RBV ) previously untreated adult participant genotype 1 genotype 4 chronic Hepatitis C Virus ( HCV ) infection .</brief_summary>
	<brief_title>A Study TMC435 Plus Pegylated Interferon Alfa-2a Ribavirin Participants With Chronic HCV Infection</brief_title>
	<detailed_description>This multicenter , international study participant receive triple therapy follow 3 medication : TMC435 also refer simeprevir ( formerly know TMC435350 ) investigational medication development treatment chronic hepatitis C virus ( HCV ) infection , pegylated interferon alfa-2a ( PegIFNα-2a ) , ribavirin ( RBV ) . PegIFNα-2a RBV commercially available therapy HCV infection . Participants receive treatment TMC435 , PegIFNα-2a , RBV 12 week . If blood level HCV ribonucleic acid ( RNA ) monitor Weeks 2 , 4 , 8 25 IU/mL , treatment stop Week 12 . If HCV RNA value 25 IU/mL Weeks 2 , 4 , 8 , treatment PegIFNα-2a RBV continue additional 12 week ( Week 24 ) unless protocol-specified stop criterion meet Week 4 12 , time treatment discontinue . The study conduct 3 phase : screen phase maximum 6 week , treatment phase extend Day 1 ( baseline ) 12 24 week depend response treatment , posttreatment follow-up period 24 week participant 's last plan dose study drug . The duration participation ( exclude screen phase ) participant vary 36 48 week , depend response treatment . Blood sample laboratory analysis obtain participant protocol-specified time point study participant safety monitor throughout study .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Simeprevir</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>treatmentnaïve confirm chronic Hepatitis C Virus ( HCV ) infection liver biopsy perform within 2 year prior screen noninvasive confirmation liver disease stage ( transient elastography ) perform within 6 month prior screen liver disease stage equivalent Metavir Score F0F2 ( fibrosis , portal fibrosis without septum ) Participants advance liver disease equivalent Metavir score F3F4 ( bridge fibrosis cirrhosis ) , hepatic decompensation , liver disease nonHCV etiology , and/or nongenotype 1 nongenotype 4 hepatitis C , hepatitis B HIV coinfection exclude study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Hepatitis C , Chronic</keyword>
	<keyword>Infection</keyword>
	<keyword>Triple therapy</keyword>
	<keyword>TMC435</keyword>
	<keyword>simeprevir</keyword>
	<keyword>Pegylated interferon alfa-2a ( PegIFNα-2a )</keyword>
	<keyword>ribavirin ( RBV )</keyword>
	<keyword>PEGASYS</keyword>
	<keyword>COPEGUS</keyword>
</DOC>